Post-Traumatic Stress Disorder (PTSD)

01Pathophysiology

PTSD results from a failure of the normal fear-extinction process following exposure to an overwhelmingly threatening event. The PPDGJ-III emphasizes that the stressor must be of an exceptionally threatening or catastrophic nature, one that would provoke distress in virtually anyone. This is not about everyday stressors; the threshold is deliberately high.

When a person experiences such an event, the amygdala becomes hyperactivated, encoding the traumatic memory with intense emotional valence. Normally, the medial prefrontal cortex (mPFC) gradually suppresses the amygdala's fear response over time, a process called fear extinction. In PTSD, this top-down inhibition fails. The amygdala remains persistently hyperresponsive, which is why patients re-experience the trauma as if it were happening again. This explains the hallmark symptom: flashbacks and intrusive recollections.

Simultaneously, the hypothalamic-pituitary-adrenal (HPA) axis becomes dysregulated. Paradoxically, cortisol levels may be low (unlike in chronic stress or depression), while catecholamine levels are elevated. This catecholamine excess drives the autonomic hyperarousal seen clinically: tachycardia, hypervigilance, exaggerated startle, and insomnia.

The hippocampus, responsible for contextualizing memories in time and place, also shows dysfunction and even volume reduction. Because the hippocampus cannot properly "time-stamp" the traumatic memory, the patient experiences flashbacks as present-tense events rather than recollections of the past. This is why a veteran may hear a car backfire and react as though under fire: the memory is retrieved without temporal context.

The emotional numbing and avoidance behaviors represent a compensatory mechanism. The brain attempts to protect itself from the overwhelming distress of re-experiencing by shutting down emotional processing and avoiding all trauma-associated cues.

02Classification and Clinical Manifestation

The PPDGJ-III organizes PTSD symptoms into several domains. Unlike DSM-5 which uses four clusters, the PPDGJ-III framework groups them somewhat differently. Below is a consolidated clinical manifestation table.

The diagnostic guideline states that the core requirement, and what distinguishes PTSD from other stress reactions, is the presence of recurrent intrusive imagery or dreams (flashbacks) of the traumatic event. Autonomic disturbance, affective symptoms, and behavioral changes can all "color" the presentation but are described as non-characteristic on their own. This means a vignette describing only anxiety and insomnia after trauma, without flashbacks or re-experiencing, should not lead you to PTSD.

The PPDGJ-III also notes that if onset exceeds 6 months but the clinical picture is classic and no better alternative diagnosis exists, the diagnosis can still be made. However, if a chronic personality change develops years or even decades after catastrophic stress, this is classified separately as enduring personality change after catastrophic experience, not as PTSD.

03Diagnostic Workup

PTSD is fundamentally a clinical diagnosis. There is no blood test, imaging study, or biomarker that confirms it. The best initial step is always a thorough clinical interview focusing on three elements: (1) the nature of the traumatic stressor, (2) the presence of re-experiencing phenomena, and (3) the temporal relationship between the event and symptom onset.

When the clinical picture is ambiguous, a structured interview tool such as the Clinician-Administered PTSD Scale (CAPS) provides the most reliable and reproducible diagnostic assessment. This is the closest thing to a "gold standard."

Laboratory testing serves only to exclude organic causes that can mimic PTSD symptoms. Hyperthyroidism can produce anxiety, tremor, tachycardia, and insomnia. Substance intoxication or withdrawal (particularly stimulants, alcohol, and cannabis) can produce flashback-like phenomena. A urine drug screen and thyroid panel are reasonable in the initial evaluation.

The PPDGJ-III sets a clear temporal criterion: onset should be within 6 months of the traumatic event. This is a frequently tested point. If the vignette describes symptom onset 3 months after a car accident, the timing fits. If the onset is 2 years later with a classic presentation and no alternative diagnosis, the PPDGJ-III allows the diagnosis but frames it as an exception, not the rule.

04Management and Treatment

In the acute phase immediately following trauma (the first hours to days), the priority is safety and stabilization, not formal therapy. Psychological first aid is the accepted approach. A frequently tested trap is critical incident stress debriefing (CISD), which was once widely used but has been shown to have no benefit and potential harm. If a vignette asks about the "next best step" immediately after a traumatic event, the answer is supportive care and safety, not formal debriefing.

For established PTSD, psychotherapy is the primary treatment. TF-CBT involves having the patient repeatedly revisit and process the traumatic memory in a controlled therapeutic setting, which facilitates the fear-extinction process that failed naturally. EMDR uses bilateral sensory stimulation (typically eye movements) during trauma recall to achieve a similar reprocessing effect. Both have strong evidence.

When pharmacotherapy is needed, either because psychotherapy alone is insufficient or because access to trained therapists is limited, SSRIs are first-line. Sertraline and paroxetine are the most evidence-based. The dose should be titrated to the therapeutic range and maintained for at least 8 to 12 weeks before judging efficacy. Premature switching is a common clinical error.

Prazosin for trauma-related nightmares is a high-yield point. It works by blocking alpha-1 receptors in the CNS, reducing the noradrenergic hyperactivity that drives nighttime re-experiencing. If a vignette describes a patient on an SSRI whose daytime symptoms are controlled but who continues to have severe nightmares, the next best step is adding prazosin.

Benzodiazepines are contraindicated in PTSD management. This is perhaps the most important pharmacotherapy pearl. They impair the consolidation of extinction learning (the very process therapy is trying to promote), carry addiction risk in a population vulnerable to substance misuse, and do not address the core pathology.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students miss PTSD questions is by ignoring the temporal criterion. The PPDGJ-III is explicit: onset must be within 6 months of the traumatic event. If a vignette describes symptom onset 8 months or more after trauma without strong justification, consider alternative diagnoses, particularly adjustment disorder or enduring personality change after catastrophe.

The second major trap involves confusing PTSD with acute stress disorder. Both share similar symptom profiles, but the distinguishing factor is duration. If the vignette timeline shows symptoms lasting only 2 weeks after a trauma, this is acute stress disorder, not PTSD, regardless of how severe the symptoms sound.

A third pitfall is the pharmacotherapy question. Many students instinctively reach for benzodiazepines when they see anxiety, insomnia, and hyperarousal. In PTSD, this is wrong. The correct first-line medication is always an SSRI. Benzodiazepines are not just suboptimal; they are actively harmful in this population.

Finally, pay close attention to what the PPDGJ-III considers the core diagnostic feature: recurrent flashbacks or intrusive imagery/nightmares of the traumatic event. Autonomic symptoms, mood changes, and behavioral disturbance are supportive but not sufficient. A vignette describing insomnia, irritability, and anxiety after trauma, but without any mention of re-experiencing, should make you question the PTSD diagnosis and consider alternatives.

The core competency being tested is your ability to (1) identify the qualifying stressor, (2) recognize re-experiencing as the cardinal feature, (3) apply the 6-month onset rule, and (4) select the correct first-line treatment while avoiding the benzodiazepine trap.